In a blow to its obesity pipeline, Pfizer drops danuglipron after liver...
Pfizer has discontinued its once-daily obesity pill danuglipron after a patient in one of its clinical trials had a liver injury that may have been drug-induced. A Pfizer spokesperson told Endpoints...
View ArticleVerve unveils early data from second attempt at heart disease gene editing
Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad...
View ArticlePharma tariffs to arrive 'in the next month or two,' commerce secretary says
Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they are “coming in the next month or two.” President Donald Trump said last week...
View ArticleIronwood to look for alternative paths after FDA asks for another Phase 3
Ironwood Pharmaceuticals is now working with Goldman Sachs in its hunt for company alternatives after getting regulatory feedback from the FDA. The Boston drugmaker hoped to get the agency's blessing...
View ArticlePrimate researchers gird for funding cuts as NIH fights court block
The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear it could cripple their work. On a typical day at the Washington National...
View ArticlePfizer's next move after ending work on oral obesity drug danuglipron
On Monday, Pfizer announced it had given up on danuglipron, the company's closely-watched, once-daily obesity pill. The move almost instantly kicked off speculation about what the company might do ...
View ArticleSandoz sues Amgen over nearly decadelong launch delay for Enbrel biosimilar
Amgen has enjoyed a monopoly on its blockbuster inflammatory disease drug Enbrel for almost 27 years now. After accumulating $86 billion in global sales, the company is still trying to keep biosimilars...
View ArticleFDA's union readies negotiations with HHS over some fired staff
A union that represents more than 11,000 FDA employees nationwide — the National Treasury Employees Union — said HHS is willing to negotiate over some fired workers, although the schedule for those...
View ArticleAMA asks UnitedHealth to relax cyberattack loan recoupment
The American Medical Association is urging Optum, a unit of UnitedHealth Group, to ease up on recouping the loans it provided to doctors’ medical practices after a cyberattack on the company’s...
View ArticleAbbVie and Sandoz resolve court spat over Rinvoq patents
AbbVie and Sandoz have resolved their patent dispute over AbbVie’s blockbuster immunology drug Rinvoq. Sandoz admitted the Rinvoq patents asserted against it are “enforceable, valid, and would be...
View ArticleBioNTech-backed ADC maker DualityBio plans Hong Kong IPO
Antibody-drug conjugates startup Duality Biologics will join the public markets on Tuesday via an initial public offering on the Hong Kong Stock Exchange. The Shanghai biotech, which has lined up...
View ArticleCDC vaccine advisors set to meet this week after two-month delay
A panel of experts who decide the national immunization schedule will meet on Tuesday for the first time in 2025, providing an opportunity for the nation’s top vaccine scientists to publicly discuss...
View ArticleBristol Myers says Camzyos fails Phase 3 study in genetic heart condition
The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the product's usage, BMS said Monday post-market, a development that could...
View ArticleTrump drug tariffs inch closer as Commerce Department launches 232 investigation
Tariffs on pharmaceutical products that President Donald Trump has teased for weeks moved one step closer on Monday, after the Commerce Department confirmed that it's launched an investigation into the...
View ArticleCell therapy startup Myeloid narrows focus as staff shrinks
Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has restructured to focus on its two clinical-stage programs, the company's CEO...
View ArticleMerck taps Cyprumed’s drug delivery platform for oral peptides
Merck is looking for ways to make its drugs easier to administer. The large pharma is licensing a drug delivery platform from Austrian biotech Cyprumed in a pact worth $493 million in upfront and...
View ArticleSmall biotech Oak Hill will bring Roche's Angelman drug back to life
Roche devastated the Angelman syndrome community in 2023, when it ended clinical development of rugonersen, a treatment candidate for the rare neurodevelopmental condition. But after
View ArticleJ&J maintains EPS, raises sales outlook under shadow of looming pharma tariffs
Johnson & Johnson is maintaining its 2025 financial guidance and raising its sales forecast despite President Donald Trump’s efforts to tariff pharmaceuticals. The growth projection for its...
View ArticleAttovia collects another $90M for I&I biologics in third funding round in two...
Attovia Therapeutics is turning fundraising announcements into an annual tradition. In June 2023, the San Carlos, CA-based startup launched with $60 million. Then in May 2024, it announced a
View Article